Press release archive

02 July 2009
GSK further extends its product portfolio in the Middle East and North Africa

26 June 2009
Seretide: Irish patent litigation update

23 June 2009
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs

23 June 2009
Regulatory update for REZONIC™ (casopitant mesylate)

16 June 2009
FDA extends review of Arzerra™ (ofatumumab)

15 June 2009
GSK announces a strategic alliance with Dr. Reddy’s to further accelerate sales growth in emerging markets

12 June 2009
GlaxoSmithKline update: A (H1N1) influenza

09 June 2009
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China

07 June 2009
Study shows GSK’s novel diabetes treatment Syncria® (albiglutide) improves glucose control and reduces weight

05 June 2009
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines

05 June 2009
World Health Organization grants Global Prequalification to GSK’s Rotarix™ vaccine

05 June 2009
Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders

02 June 2009
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs

01 June 2009
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer

29 May 2009
FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)

22 May 2009
US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system

15 May 2009
GlaxoSmithKline update: A (H1N1) influenza vaccine development

12 May 2009
GSK extends strategic collaboration with Aspen

08 May 2009
New data for GlaxoSmithKline’s vaccine, Cervarix®, presented at IPV Conference

08 May 2009
Community healthcare charities receive £300,000 from GlaxoSmithKline in recognition of their work

06 May 2009
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million

01 May 2009
GlaxoSmithKline update: influenza A (H1N1)

27 April 2009
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease

27 April 2009
Emergence of a new H1N1 influenza A strain (swine influenza)

20 April 2009
GlaxoSmithKline launches alli® (orlistat 60 mg)

20 April 2009
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business

16 April 2009
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company

01 April 2009
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US

31 March 2009
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation

30 March 2009
Cervarix® U.S. regulatory update

24 March 2009
GSK publishes 2008 Corporate Responsibility Report

19 March 2009
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.

05 March 2009
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)

04 March 2009
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer

17 February 2009
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)

06 February 2009
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV

05 February 2009
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer

05 February 2009
Results announcement for the fourth quarter 2008

04 February 2009
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma

02 February 2009
GlaxoSmithKline plc, announces board changes

30 January 2009
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer

30 January 2009
Deirdre Connelly to join GSK as President, North American Pharmaceuticals

29 January 2009
GSK announces charges for legal matters

29 January 2009
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

23 January 2009
GSK to drive growth in emerging markets with acquisition of UCB products

22 January 2009
GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe

21 January 2009
GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)

09 January 2009
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome

07 January 2009
GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.

23 December 2008
Cytokinetics retains development and commercialization rights to ispinesib and SB-743921

23 December 2008
GlaxoSmithKline and Archemix form strategic alliance to develop aptamers to treat inflammatory diseases

22 December 2008
GlaxoSmithKline to cease providing corporate political contributions

22 December 2008
GSK and Theravance announce positive phase 2b results for LABA `444 in the treatment of COPD in the Horizon Development Programme

22 December 2008
GSK to acquire BMS Pakistan

19 December 2008
GSK files for European Marketing Authorisation of Duodart® for benign prostatic hyperplasia

18 December 2008
GSK initiates phase lll programme for novel cardiovascular medication, darapladib

17 December 2008
GlaxoSmithKline and Dynavax announce worldwide strategic alliance

12 December 2008
'Green' canal water helps fuel 21st century business

11 December 2008
GlaxoSmithKline statement on FDA Advisory Committee vote on use of asthma medicines containing long-acting beta-agonists

11 December 2008
Tyverb®/Tykerb® (lapatinib) plus letrozole significantly delayed disease progression in post-menopausal women with ErbB2 positive metastatic breast cancer

08 December 2008
Arzerra™ (ofatumumab) demonstrates high response rates in patients with fludarabine refractory chronic lymphocytic leukemia (CLL)

08 December 2008
GlaxoSmithKline extends tender offer for Genelabs Technologies, Inc.

08 December 2008
Two new studies in the New England Journal of Medicine show malaria vaccine candidate advancing in Africa

06 December 2008
GSK reports Promacta®/Revolade® (eltrombopag) significantly increased platelet counts and reduced bleeding in long-term study of patients with chronic ITP

05 December 2008
GSK analysis shows Seretide/Advair is a well tolerated and effective medicine for controlling asthma

04 December 2008
GlaxoSmithKline and The Carter Center reaffirm commitment to global public health with expansion of LF program

03 December 2008
GSK announces waiver of a condition to the tender offer for Genelabs Technologies

02 December 2008
GSK and Theravance announce positive phase 2b results for LABA, `444 in the Horizon Asthma Development programme

21 November 2008
GSK and Neptunus sign cooperation agreement to form joint venture for the co-development of flu vaccines in China, Hong Kong and Macau

20 November 2008
FDA approves Promacta® (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder

20 November 2008
GSK to strengthen OTC analgesic business with acquisition of Alvedon

20 November 2008
Cervarix, GSK’s cervical cancer vaccine, wins tender for Dutch national immunisation programme

12 November 2008
GSK commences tender offer to acquire Genelabs Technologies, Inc.

11 November 2008
GSK proposes to close Dartford manufacturing site in the UK by 2013

10 November 2008
GSK and Xenoport announce plans to withdraw and resubmit new drug application requesting approval of Solzira™ for restless legs syndrome

29 October 2008
GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies for Hepatitis C

23 October 2008
GSK receives positive CHMP opinion for new non-prescription weight loss treatment – alli® – to help in the fight against obesity across Europe

23 October 2008
GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines

22 October 2008
Results announcement for the third quarter 2008

21 October 2008
GlaxoSmithKline to acquire the leading dry mouth brand, Biotene

15 October 2008
GSK’s Emerging Markets strategy advances with acquisition in Egypt

14 October 2008
GSK responds to NICE’s second technology appraisal consultation document on the use of Tyverb, in combination with capecitabine, for women with previously treated advanced or metastatic breast cancer

08 October 2008
LF Elimination programme treats over half billion people and protects millions more from debilitating disease

19 September 2008
GSK update on FDA review of Promacta® (eltrombopag)

16 September 2008
New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning

16 September 2008
GSK and Xenoport announce submission of new drug application requesting FDA approval of Solzira™ for Restless Legs Syndrome

15 September 2008
Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer

14 September 2008
Tyverb® demonstrates encouraging results in Phase II study in advanced head and neck cancer

12 September 2008
ESMO 2008 - GlaxoSmithKline to present encouraging new data supporting late stage development programme

10 September 2008
GlaxoSmithKline and Cellzome announce major strategic alliance

09 September 2008
Ellen Strahlman appointed Chief Medical Officer at GlaxoSmithKline

08 September 2008
GlaxoSmithKline plc – Directorate change

02 September 2008
GlaxoSmithKline’s darapladib modifies coronary plaque composition and lowers Lp-PLA2 activity, a biomarker predictive of heart attack risk

28 August 2008
GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement for retigabine

31 July 2008
GlaxoSmithKline and Genmab announce positive top-line results in ofatumumab chronic lymphocytic leukaemia pivotal study

24 July 2008
GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration to enable the discovery of new medicines

23 July 2008
Results announcement for the second quarter 2008

23 July 2008
GSK sets out new strategic priorities

23 July 2008
GSK enters transformational agreement with Aspen to drive growth in emerging markets

22 July 2008
Dan Troy appointed as Senior Vice President and General Counsel for GlaxoSmithKline

21 July 2008
GlaxoSmithKline teams up with academia to develop new medicines of value

21 July 2008
GlaxoSmithKline reaches settlement agreement with Biota

14 July 2008
GlaxoSmithKline and Actelion enter into exclusive collaboration to realise the full potential of almorexant in sleep disorders and beyond

07 July 2008
GSK receives BITC CommunityMark for global community programmes

01 July 2008
GlaxoSmithKline to appeal judgment in Alabama Medicaid pricing suit

30 June 2008
GSK and Aspen enter product divestment agreement

30 June 2008
GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval

18 June 2008
Cervarix™, GSK’s cervical cancer vaccine, wins tender for UK national immunisation programme

18 June 2008
GlaxoSmithKline responds to Government announcement on the PPRS

16 June 2008
GlaxoSmithKline and Mpex Pharmaceuticals form alliance to develop novel efflux pump inhibitors for use against serious gram-negative infections

15 June 2008
Revolade® (eltrombopag) data presented at EHA: updated data for EXTEND plus new data for REPEAT and DELPHI studies

13 June 2008
US FDA approves Requip® XL™, the first and only oral once-daily non-ergot dopamine agonist for Parkinson’s disease

12 June 2008
GlaxoSmithKline receives marketing authorisation in the EU for Tyverb® (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer

11 June 2008
Phase III data show GSK paediatric candidate vaccine’s potential to provide improved protection against life-threatening pneumococcal diseases

10 June 2008
Results from one year study suggest Seretide/Advair provides important benefits for African American patients with asthma

06 June 2008
GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc., a world leader in sirtuin research and development

03 June 2008
GlaxoSmithKline and Boston’s Immune Disease Institute put scientists head-to-head in race for new discoveries

02 June 2008
GlaxoSmithKline successfully completes tender offer for shares of Sirtris Pharmaceuticals

01 June 2008
New data offer insights into the potential role for Tykerb® / Tyverb® (lapatinib) in non-cytotoxic chemotherapy-based treatment regimens

31 May 2008
New data for pazopanib – GSK’s latest investigational anti-cancer agent – shows promise across multiple cancers

30 May 2008
New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma

29 May 2008
GlaxoSmithKline announces new drug application and Phase III results for Rezonic™ / Zunrisa™ (casopitant)

22 May 2008
GlaxoSmithKline announces $500,000 in fellowships at Stanford Graduate School of Business

21 May 2008
GlaxoSmithKline plc - results of AGM

20 May 2008
Elesclomol study shows significant improvement in progression-free survival for chemotherapy-naïve patients with metastatic melanoma

19 May 2008
First pre-pandemic vaccine approved to help protect against pandemic influenza

16 May 2008
GSK announces results of first Phase III trial evaluating Tykerb®/Tyverb® (lapatinib) plus Herceptin® (trastuzumab)

15 May 2008
The battle against obesity: European experts and pharmacists call for an increased role for pharmacy

14 May 2008
Scientists publishing in Nature call for the diversification of antiviral stockpiles in preparation for an influenza pandemic

14 May 2008
Cervarix™ provides longest duration of sustained neutralising antibodies reported for any vaccine against HPV 16 and 18 to date

12 May 2008
Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial

02 May 2008
GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals

30 April 2008
FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD

30 April 2008
GSK announces changes to Corporate Executive Team

29 April 2008
GlaxoSmithKline awards £300,000 to community health charities in recognition of their work

25 April 2008
GlaxoSmithKline's Volibris (ambrisentan) receives authorisation from the European Commission for the treatment of Functional Class II and III Pulmonary Arterial Hypertension

25 April 2008
GSK receives positive opinion for conditional approval of new oral breast cancer treatment, Tyverb (lapatinib)

23 April 2008
Results announcement for the first quarter 2008

22 April 2008
GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development

22 April 2008
GlaxoSmithKline gains approval for co-administration of Avodart® (dutasteride) with tamsulosin for the treatment of benign prostatic hyperplasia under the European Mutual Recognition Procedure

22 April 2008
GlaxoSmithKline reports further progress of oncology portfolio

18 April 2008
New data demonstrate that lapatinib decreases tumourigenic breast cancer stem cells in women receiving neoadjuvant treatment

17 April 2008
GlaxoSmithKline and Regulus Therapeutics form strategic alliance to develop microRNA targeted therapeutics to treat inflammatory diseases

15 April 2008
Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine

08 April 2008
GlaxoSmithKline confirms receipt of FDA letter on regulatory reporting

04 April 2008
FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunisation series by four months of age

02 April 2008
GlaxoSmithKline statement - Lancet publication of D:A:D data

19 March 2008
GSK charitable support valued at GBP282 million in 2007

18 March 2008
Tyverb (lapatinib) European regulatory update

16 March 2008
Phase III study of Bosatria (mepolizumab) showed disease control with reduced corticosteroid use in hypereosinophilic syndrome

06 March 2008
GSK statement on MHRA investigation

03 March 2008
FDA grants Priority Review For Promacta / Revolade (Eltrombopag)

29 February 2008
Update on GSK's malaria treatments: Dacart and Lapdap

28 February 2008
XenoPort and GlaxoSmithKline report positive top-line results of final pivotal trial of XP13512/GSK1838262 for restless legs syndrome

26 February 2008
GlaxoSmithKline statement: Public Library of Science Medicine article on antidepressant medicines

26 February 2008
GlaxoSmithKline and Theravance announce expansion of the Horizon programme with start of large Phase 2B study of LABA in COPD patients

21 February 2008
GSK's Volibris (ambrisentan) receives EMEA positive opinion for approval to treat class II and II pulmonary arterial hypertension (PAH)

19 February 2008
New price reductions for GSK antiretrovirals in the world's poorest countries

08 February 2008
Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia

08 February 2008
FDA extends review of NDA for Entereg® (alvimopan)

07 February 2008
Full-year results announcement 2007

06 February 2008
GlaxoSmithKline responds to findings in ACCORD study

04 February 2008
GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer

04 February 2008
GlaxoSmithKline and Amira Pharmaceuticals enter global agreement for FLAP inhibitor programme

31 January 2008
GlaxoSmithKline files pneumococcal paediatric vaccine in the EU

28 January 2008
GlaxoSmithKline welcomes European guidance that stockpiling more than one antiviral would be useful in preparing for a flu pandemic

28 January 2008
GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA

24 January 2008
GSK appoints Lon Cardon to focus genetics on new disease targets

24 January 2008
GSK and MRC to identify new therapeutic targets and biomarkers from genetic association studies

24 January 2008
GlaxoSmithKline and TB Alliance renew tuberculosis drug discovery programme

24 January 2008
GlaxoSmithKline and Medicines For Malaria Venture announce new collaboration to investigate novel antimalarial compounds

24 January 2008
GlaxoSmithKline to revise Avandia® (rosiglitazone maleate) label in Europe following assessment by CHMP

23 January 2008
GlaxoSmithKline and Adolor report favourable FDA Advisory Committee meeting for Entereg® (alvimopan) for the management of postoperative ileus in bowel resection

15 January 2008
New allergic rhinitis treatment Avamys™ approved in Europe

15 January 2008
GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262

03 January 2008
GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and LABA studies for asthma in the Horizon programme

28 December 2007
First head-to-head study comparing common treatments for patients with COPD shows quality of life and survival benefits for patients treated with Seretide

20 December 2007
GlaxoSmithKline files for FDA approval of Promacta/Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder

19 December 2007
GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals

19 December 2007
GlaxoSmithKline completes acquisition of Reliant Pharmaceuticals

17 December 2007
GlaxoSmithKline receives FDA ‘complete response’ letter for cervical cancer vaccine

16 December 2007
GlaxoSmithKline announces data on Tykerb® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases

14 December 2007
GlaxoSmithKline, via its Centre Of Excellence for External Drug Discovery, exercises its options to further develop and commercialise Exelixis’ anti-cancer C-Met inhibitior XL880

13 December 2007
GlaxoSmithKline presents innovative neuroscience pipeline

11 December 2007
GlaxoSmithKline responds to JAMA article on the ICES thiazolidinediones and cardiovascular outcomes in older patients with diabetes

10 December 2007
GlaxoSmithKline receives decision from US FDA on Requip® XL™

10 December 2007
Long-term safety and efficacy data on Promacta™ (eltrombopag) presented at American Society of Hematology Annual Meeting

10 December 2007
GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to develop cancer stem cell antibody therapeutics

10 December 2007
GlaxoSmithKline and Galapagos enter strategic alliance to develop novel antibacterials and antivirals

07 December 2007
GlaxoSmithKline announces appointments to the Board of Directors

06 December 2007
GSK’s continued commitment to fighting HIV/AIDS results in approval of new formulations of three medicines for the treatment of children

04 December 2007
Statement from GlaxoSmithKline: publication of update regarding thiazolidinediones to treatment guidelines for the management of type 2 diabetes mellitus by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA)

03 December 2007
GSK response to Nature Medicine article on rosiglitazone and bone in mice

28 November 2007
GSK statement on US Food and Drug Administration Pediatric Advisory Committee recommendations regarding salmeterol

26 November 2007
GlaxoSmithKline obtains exclusive US OTC marketing rights to Mevacor® (lovastatin) from Merck & Co., Inc.

23 November 2007
New data published in The Lancet show GSK's rotavirus vaccine Rotarix offers sustained and broad protection against all common circulating rotavirus types

21 November 2007
GlaxoSmithKline to acquire Reliant Pharmaceuticals

20 November 2007
GlaxoSmithKline and Genmab initiate ofatumumab rheumatoid arthritis Phase III programme

15 November 2007
GSK and the European Foundation for the Study of Diabetes (EFSD) commit €1 million to diabetes research in Europe

14 November 2007
GlaxoSmithKline revises US labeling for Avandia

07 November 2007
Prometheus to acquire Lotronex® from GlaxoSmithKline

05 November 2007
GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response

05 November 2007
New innovation grants boost malaria advocacy efforts in Africa

02 November 2007
Fabre Kramer Pharmaceuticals receives decision from FDA on gepirone ER for major depressive disorder

24 October 2007
Results announcement for the third quarter 2007

23 October 2007
GlaxoSmithKline and Tolerx form worldwide collaboration for development and commercialisation of novel medication

19 October 2007
New allergic rhinitis treatment Avamys™ receives positive opinion in Europe

18 October 2007
European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment

17 October 2007
New Lancet study: Malaria vaccine candidate has promising safety, tolerability profile in infants

15 October 2007
GSK receives approval for Hycamtin® (topotecan) capsules for the treatment of relapsed small cell lung cancer

10 October 2007
GlaxoSmithKline and Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology

08 October 2007
GlaxoSmithKline appoints Andrew Witty CEO designate

08 October 2007
GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry

04 October 2007
GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe

02 October 2007
GSK applies for licence to market OTC weight loss product In Europe

28 September 2007
GSK submits Cervarix licence application to Japan's health authorities

28 September 2007
GlaxoSmithKline plc announces change to the Board of Directors

27 September 2007
GlaxoSmithKline helps form the Serious Adverse Events Consortium

25 September 2007
GlaxoSmithKline named to Working Mother "100 Best Companies" list

24 September 2007
Cervarix, GSK's cervical cancer vaccine, approved In Europe

21 September 2007
GSK receives decision from FDA on Lamictal®XR™ Extended-Release Tablets

11 September 2007
GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia

11 September 2007
GlaxoSmithKline responds to JAMA articles

04 September 2007
Study shows combination therapy incorporating Avodart® and tamsulosin provides continuous symptom improvement over two years

03 September 2007
GlaxoSmithKline's Arixtra® receives European authorisation for the treatment of acute coronary syndromes

28 August 2007
FDA accepts for review complete response to approvable letter for Entereg® (alvimopan) for POI

28 August 2007
GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe for the treatment of difficult-to-treat leukaemias and lymphomas

16 August 2007
GlaxoSmithKline signs contract for its pandemic flu vaccine with UK Government

14 August 2007
GlaxoSmithKline's application for Rotarix® is accepted for review by the FDA

14 August 2007
GlaxoSmithKline updates prescribing information for Avandia in the US

08 August 2007
GSK gives consent under Canada's Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda

08 August 2007
GSK receives decision from FDA on Advair 500/50 for COPD

03 August 2007
GlaxoSmithKline receives new HHS order for H5N1 bulk antigen

02 August 2007
FDA issues second approvable letter for Trexima™

02 August 2007
GSK comments on UK Government announcement to renegotiate current Pharmaceutical Pricing and Regulation Scheme agreement

30 July 2007
GlaxoSmithKline presents Avandia data to FDA

30 July 2007
Pharmetrics epidemiology study

30 July 2007
FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US

27 July 2007
GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis [1]

27 July 2007
GlaxoSmithKline and Targacept form alliance in therapeutics for CNS-related disorders

25 July 2007
New head-to-head study comparing Lexiva® and atazanavir show similar efficacy and lipid changes

25 July 2007
Results announcement for the second quarter 2007

18 July 2007
GSK's cervical cancer candidate vaccine Cervarix™ receives positive opinion in Europe for prevention of cervical cancer

17 July 2007
GSK responds to online review of rosiglitazone by The Cochrane Collaboration

09 July 2007
GSK receives extended licence indication for Seretide in Europe following submission of TORCH data for COPD

27 June 2007
Largest cervical cancer vaccine efficacy trial shows Cervarix™ provides excellent protection against lesions caused by most common cancer-causing virus types

25 June 2007
GlaxoSmithKline's Arixtra® (fondaparinux sodium) receives positive opinion in Europe for the treatment of acute coronary syndromes

24 June 2007
New data show patients treated with Avandia® (rosiglitazone maleate) incurred lower medical costs and used fewer healthcare resources when compared to patients treated with sulphonylureas

22 June 2007
GlaxoSmithKline's Atriance (nelarabine) receives positive opinion in Europe for the treatment of rare, difficult to treat leukaemias and lymphomas

18 June 2007
GlaxoSmithKline expects to launch up to five major new medicines for oncology in next three years

15 June 2007
GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)

13 June 2007
GlaxoSmithKline, Imperial College London, and The Medical Research Council officially open the UK's world-leading Clinical Imaging Centre

13 June 2007
GlaxoSmithKline to make unprecedented vaccine donation to WHO pandemic flu stockpile

13 June 2007
GlaxoSmithKline's application for DTaP-IPV vaccine is accepted for review by the FDA

12 June 2007
alli™ - the OTC weight loss product - on shelves nationwide in the US later this week

12 June 2007
FDA grants priority review for oral formulation of HYCAMTIN (topotecan) to treat relapsed small cell lung cancer

11 June 2007
GlaxoSmithKline and Adolor update alvimopan (Entereg/Entrareg) development programme

09 June 2007
Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP

06 June 2007
Newly published data from large study support cardiovascular safety of Avandia (rosiglitazone maleate)

06 June 2007
Statement of Moncef Slaoui, PhD, Chairman Research & Development, GlaxoSmithKline

05 June 2007
Encouraging clinical activity of GSK's novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer

05 June 2007
Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age

05 June 2007
Interim data from RECORD study show no significant difference between Avandia and standard therapy in risk of cardiovascular hospitalization or death

05 June 2007
GlaxoSmithKline response to New England Journal of Medicine editorials

04 June 2007
GSK's pazopanib shows positive results in patients with advanced renal cell carcinoma, ovarian cancer and soft tissue sarcoma

04 June 2007
Eight-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR

03 June 2007
GlaxoSmithKline reports positive new data on Tykerb (lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) annual meeting

01 June 2007
GlaxoSmithKline announces Altargo approved in Europe for treatment of Impetigo and other skin infections

01 June 2007
GlaxoSmithKline honours cancer research pioneer Gianni Bonadonna with new ASCO award and fellowship

30 May 2007
Data affirms Avandia (rosiglitazone maleate) cardiovascular safety profile

25 May 2007
Retrospective observational study shows combination vaccines may improve vaccination coverage rates in infants

24 May 2007
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai

23 May 2007
GlaxoSmithKline announces Swiss approval of Tyverb®, a new oral treatment for advanced breast cancer

23 May 2007
GlaxoSmithKline plc - results of AGM

22 May 2007
alli™ debuts through the alli Experience

21 May 2007
Cervarix™ is approved in Australia for females 10-45 years old

21 May 2007
GlaxoSmithKline responds to NEJM article on Avandia

21 May 2007
GlaxoSmithKline strongly defends its record on Avandia

17 May 2007
Sally Field addresses members of Congress about osteoporosis during national osteoporosis awareness month

11 May 2007
GlaxoSmithKline's Hib-MenCY-TT combination vaccine meets phase II study endpoints of immunogenicity and safety compared to licensed vaccines

10 May 2007
Cervarix® data show that higher levels of antibodies in the bloodstream correlate to higher levels in cervico-vaginal secretions

08 May 2007
Fabre-Kramer refiles gepirone ER with the FDA for the treatment of major depressive disorder

07 May 2007
GlaxoSmithKline's investigational DTaP-IPV combination vaccine shown to be immunogenic and well-tolerated in Phase III clinical trial

02 May 2007
GlaxoSmithKline supports World Health Organization efforts to strengthen global pandemic preparedness plans

02 May 2007
Trexima™ (sumatriptan/naproxen sodium) provided relief of both traditional and non-traditional migraine symptoms

02 May 2007
Trexima™ (sumatriptan/naproxen sodium) demonstrated efficacy across multiple migraine attacks

01 May 2007
FDA Advisory Committee finds substantial evidence to support Advair 500/50 in reducing COPD exacerbations

01 May 2007
New data shows once a day Lamictal® XR™ is effective in treating patients with partial seizures

30 April 2007
GlaxoSmithKline and Wellcome Trust announce partnership to target drug-resistant hospital infections

27 April 2007
FDA approves once-daily Veramyst (fluticasone furoate) Nasal Spray for treatment of seasonal and year-round allergy symptoms in adults and children as young as two years

25 April 2007
Results announcement for the first quarter 2007

18 April 2007
GlaxoSmithKline receives Japanese approval for two major new product opportunities: Seretide/Advair and Arixtra

18 April 2007
Community health charities receive £265,000 in recognition of their work from GlaxoSmithKline

17 April 2007
Cervarix®, GSK cervical cancer candidate vaccine, demonstrates 100 percent protection against precancerous lesions caused by cancer-causing human papillomavirus types 16 & 18 for more than five years

12 April 2007
GSK initiates repeat dosing study of its novel oral platelet growth factor, eltrombopag, in ITP

12 April 2007
GSK announces FDA approval of Altabax (retapamulin ointment), 1%

09 April 2007
GSK and Adolor announce preliminary results from phase 3 Safety study of Alvimopan (Entereg/Entrareg)

03 April 2007
Once daily, extended-release ropinirole improves Parkinson's symptoms in patients not optimally controlled with levodopa

03 April 2007
Trexima (sumatriptan/naproxen sodium) superior efficacy data published in JAMA

02 April 2007
GlaxoSmithKline KK seeks approval in Japan for lapatinib, a new treatment for breast cancer

02 April 2007
FDA approves accelerated dosing schedule for GlaxoSmithKline's Twinrix

30 March 2007
GlaxoSmithKline files meningococcal conjugate vaccine

29 March 2007
GlaxoSmithKline submits biologics license application to US Food and Drug Administration for Cervarix

29 March 2007
GlaxoSmithKline appoints Zhi Hong to head infectious-diseases research centre

26 March 2007
New study indicates nicotine patches may be safe for helping patients with coronary artery disease to quit smoking

23 March 2007
GlaxoSmithKline announces Altargo receives positive opinion in Europe for treatment of impetigo and other skin infections

22 March 2007
GSK giving figures exceed £300 million for fourth year running: medicines for Lymphatic Filariasis elimination valued at £16 million

22 March 2007
GSK announces nationwide availability of once-a-day Coreg CR for the treatment of three key cardiovascular conditions

20 March 2007
FiberChoice plus multivitamins issues allergy alert

13 March 2007
FDA approves Tykerb (lapatinib) in combination with Xeloda (capecitabine) for the treatment of advanced or metastatic breast cancer in women who have progressed on prior therapy

09 March 2007
New JACC analysis details cardiovascular protective benefits of carvedilol in heart failure patients

05 March 2007
New studies indicate GSK's pre-pandemic influenza vaccine can protect against different strains of H5N1

01 March 2007
Study published in New England Journal of Medicine: Vaccine 95.5% effective against neglected hepatitis E

27 February 2007
New data show fluticasone furoate nasal spray effectively treated nasal symptoms of allergic rhinitis

26 February 2007
GSK initiates first global Phase III study of Tykerb (lapatinib) in head and neck cancer

21 February 2007
Landmark study shows important benefits of Seretide treatment for patients with fatal lung disease, COPD

20 February 2007
GlaxoSmithKline acquires exclusive rights to over-the-counter orlistat for markets outside the US from Roche Group

20 February 2007
OFT market study into the Pharmaceutical Price Regulation Scheme

16 February 2007
GlaxoSmithKline successfully completes tender offer for shares of Praecis Pharmaceuticals

16 February 2007
GlaxoSmithKline Diseases of the Developing World ad campaign receives industry award

13 February 2007
WHO awards prequalification status to GSK rotavirus vaccine

13 February 2007
GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B in systemic lupus erythematosus

13 February 2007
GlaxoSmithKline offers new tools to help patients get free medicines

12 February 2007
GlaxoSmithKline plc announces change to the Board of Directors

09 February 2007
GlaxoSmithKline commends $1.5 billion advance market commitment for pneumococcal vaccines

08 February 2007
Full-year results announcement 2006

08 February 2007
GlaxoSmithKline and XenoPort announce agreement on late-stage compound for RLS and neuropathic pain

08 February 2007
GlaxoSmithKline and Fabre-Kramer Pharmaceuticals enter global agreement for new treatment of major depressive disorder

07 February 2007
FDA approves alli (orlistat 60 mg capsules) over-the-counter

07 February 2007
GlaxoSmithKline accepts shares in tender offer for shares of Praecis Pharmaceuticals and commences subsequent offering period

02 February 2007
GlaxoSmithKline receives approvable letter for new indications for Arixtra (fondaparinux sodium) injection

02 February 2007
Valtrex (valacyclovir) - US patent litigation update

29 January 2007
GlaxoSmithKline statement - BBC Panorama - 29 January 2007

29 January 2007
GlaxoSmithKline files its new pre-pandemic influenza vaccine in Europe

18 January 2007
GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines

17 January 2007
GlaxoSmithKline awarded $63 million HHS contract for pandemic vaccine research and development: Company begins government and retail shipments of its antiviral Relenza

16 January 2007
GlaxoSmithKline receives first European approval for Wellbutrin XR

09 January 2007
GlaxoSmithKline commences tender offer to acquire Praecis Pharmaceuticals

27 December 2006
Landmark Tykerb (lapatinib) data published in the New England Journal of Medicine

22 December 2006
GSK receives approvable letter for topical antibiotic, Altabax (retapamulin ointment), 1%

21 December 2006
GlaxoSmithKline to acquire Praecis Pharmaceuticals

19 December 2006
GlaxoSmithKline and Genmab enter global agreement for HuMax-CD20

19 December 2006
Adrian Rawcliffe to lead GlaxoSmithKline's Worldwide Business Development

19 December 2006
GlaxoSmithKline completes acquisition of CNS, Inc.

18 December 2006
GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)

15 December 2006
GlaxoSmithKline reaches EU regulatory milestone in its flu pandemic vaccine development programme

13 December 2006
Lapatinib (Tykerb) to be evaluated in early stage disease in adjuvant breast cancer settings internationally

12 December 2006
GlaxoSmithKline and EPIX Pharmaceuticals enter drug discovery and development alliance

11 December 2006
Trial data showed eltrombopag decreased bleeding episodes and improved platelet counts in patients with chronic idiopathic thrombocytopenic purpura

08 December 2006
GlaxoSmithKline to acquire Domantis for £230 million

06 December 2006
Novel oral platelet growth factor, eltrombopag, to be evaluated in long term ITP study

04 December 2006
Landmark study shows Avandia is more effective than metformin or a sulphonylurea in long-term blood sugar control in type 2 diabetes

01 December 2006
Hycamtin indication expanded to include treatment of cervical cancer in combination with chemotherapy

29 November 2006
GlaxoSmithKline welcomes decision by GAVI Alliance to support introduction of new vaccines against rotavirus and pneumococcal disease

29 November 2006
Bill Louv appointed Senior Vice President, Information Technology; Ford Calhoun to retire from GSK

20 November 2006
GSK to supply and store H5N1 vaccine products for US flu pandemic stockpiling

15 November 2006
GlaxoSmithKline and NeuroSearch expand the scope of strategic alliance

15 November 2006
National survey reveals striking lack of understanding about common, life-threatening lung disease that affects millions

13 November 2006
GlaxoSmithKline welcomes new GINA guidelines for Asthma Management and Prevention

13 November 2006
GSK joins with HHS and CDC to encourage flu vaccinations

11 November 2006
New data show fewer visits and hospitalizations among asthma patients treated with Advair Diskus

11 November 2006
New survey data reveal majority of asthma patients remain uncontrolled based on scores from the Asthma Control Test

06 November 2006
FDA issues approvable letter for Entereg for POI

30 October 2006
Eltrombopag significantly improved platelet count and allowed initiation of antiviral therapy in majority of hepatitis C patients

26 October 2006
Results announcement for the third quarter 2006

20 October 2006
FDA approves new, once-a-day COREG CR for the treatment of three key cardiovascular conditions

18 October 2006
Switzerland to purchase GSK's H5N1 vaccine for pre-pandemic use

18 October 2006
GlaxoSmithKline's new generation flu vaccine shows a significant increase in seroprotection rate in the over 65 population

12 October 2006
GlaxoSmithKline sponsors HIV Medicine Association Minority Fellowship Program

11 October 2006
GlaxoSmithKline submits supplemental drug application in the USA for Advair in COPD

09 October 2006
GlaxoSmithKline seeks European approval for Tykerb (lapatinib ditosylate) for the treatment of advanced breast cancer

09 October 2006
GlaxoSmithKline to acquire CNS, Inc.

05 October 2006
GSK's new flu vaccine, FluLaval, provides Americans with a new option for fighting the flu

02 October 2006
FDA grants priority review for Arixtra (fondaparinux sodium) in the treatment of acute coronary syndromes

29 September 2006
GlaxoSmithKline strengthens global vaccine manufacturing network with investment of Euros 500m in production facility in France

29 September 2006
Mathematical model predicts that Cervarix may prevent nearly 80% of cervical cancers

28 September 2006
GlaxoSmithKline grants license for manufacture of influenza treatment zanamivir

28 September 2006
New data reinforce efficacy of Trizivir alone in treatment-naive HIV patients with low viral load

28 September 2006
GlaxoSmithKline and Vertex Pharmaceuticals announce virologic and drug resistance results from protease inhibitor study

27 September 2006
GSK statement: Court of First Instance judgement

25 September 2006
FDA approves new epilepsy indication for Lamictal

25 September 2006
GlaxoSmithKline named to Working Mother Hall of Fame

20 September 2006
New data show peak concentration of sumatriptan occurred earlier with Trexima (sumatriptan succinate/naproxen sodium) compared to Imitrex (sumatriptan succinate)

20 September 2006
New data show consistent efficacy and tolerability of Trexima (sumatriptan succinate/naproxen sodium) across multiple migraine attacks

20 September 2006
New analysis shows patients who treat their migraine pain early with Trexima (sumatriptan succinate/naproxen sodium) have higher sustained pain-free rates than those who treat late

18 September 2006
GlaxoSmithKline seeks US approval for Tykerb (lapatinib ditosylate) for the treatment of advanced breast cancer

15 September 2006
GlaxoSmithKline agrees preferential prices for HIV medicines in Russia

15 September 2006
Avandia reduces risk of progression from pre-diabetes to type 2 diabetes by 62 per cent in largest ever diabetes prevention trial

12 September 2006
GlaxoSmithKline submits Seretide TORCH study data to EU regulators

11 September 2006
GSK settles transfer pricing tax dispute with IRS

08 September 2006
GlaxoSmithKline Award for Outstanding Achievement in Chemical Biology granted to Professor Herbert Waldmann, Max-Planck Institute

07 September 2006
Low-dose orlistat provides significant weight loss and multiple health benefits

05 September 2006
GlaxoSmithKline receives positive decision in Greek parallel trade case

05 September 2006
GlaxoSmithKline and Adolor report top line results from phase 3 studies of alvimopan (Entereg/Entrareg)

04 September 2006
New study reveals investigational 24-hour formulation of Requip (ropinirole HCI) tablets reduced "off" time for patients with Parkinson's disease

24 August 2006
GlaxoSmithKline and ChemoCentryx enter into drug discovery and development alliance in inflammatory disorders

24 August 2006
GlaxoSmithKline receives approval in 15 European countries for use of Relenza in prevention of influenza A and B

14 August 2006
Updated HIV treatment guidelines now include three GSK HIV medications for initial antiretroviral treatment regimens

10 August 2006
GSK patents and patent applications for Combivir

10 August 2006
GlaxoSmithKline reaches civil settlements on AWP matters

27 July 2006
New seasonal and perennial rhinitis intranasal treatment submitted for US and European marketing approval

27 July 2006
Sri Lanka conducts its final national lymphatic filariasis mass drug distribution

26 July 2006
GSK reports significant advance in H5N1 pandemic flu vaccine programme

26 July 2006
Results announcement for the second quarter 2006

24 July 2006
Pivotal studies begin for new antimalarial in sub-Saharan Africa

21 July 2006
Biopsy study shows combination of long-acting beta2-agonist and low steroid dose in Advair Diskus 100/50mcg maintains control of airway inflammation

20 July 2006
GSK announces US government purchase of Relenza for state stockpiles

12 July 2006
Latest data show GlaxoSmithKline's proprietary adjuvant system for Cervarix induces a stronger and more sustained immune response than a conventional adjuvant formulation

12 July 2006
More than five million smokers successfully smoke-free since therapeutic nicotine made available over-the-counter a decade ago

11 July 2006
GlaxoSmithKline announces FDA approval and the launch of Avandamet (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes

06 July 2006
Study finds that co-administration of LEXIVA with esomeprazole does not affect blood levels of LEXIVA

29 June 2006
GlaxoSmithKline files for European marketing approval for Atriance as treatment for rare leukaemia and lymphoma

29 June 2006
GlaxoSmithKline plc announces change to the Board of Directors

26 June 2006
Multicultural Marketing and Diversity Awards focus on using key insights to reach employees, customers, consumers, patients and external stakeholders

22 June 2006
GlaxoSmithKline and INSEAD inaugurate a Chair in Corporate Innovation

19 June 2006
Study analysis shows that eltrombopag significantly improves platelet count and response rates in idiopathic thrombocytopenic purpura (ITP)

15 June 2006
GlaxoSmithKline announces expanded indication for Hycamtin to treat cervical cancer in combination chemotherapy

13 June 2006
New treatment provides relief of both nasal and ocular symptoms in seasonal allergic rhinitis

12 June 2006
FDA approves Wellbutrin XL (bupropion HCl extended-release tablets) for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder

10 June 2006
New data demonstrate benefits of initial use of Avandaryl (rosiglitazone maleate and glimepiride) in people with type 2 diabetes

07 June 2006
GlaxoSmithKline and Galapagos enter into drug discovery and development alliance in osteoarthritis

07 June 2006
Bob Harper of NBC's "The Biggest Loser" partners with national diabetes experts to help Americans step up their diabetes management

06 June 2006
PATH to pave the way for cervical cancer vaccines in the developing world

05 June 2006
GSK licenses cancer antigen portfolio from Ludwig Institute for Cancer Research

05 June 2006
New data show Cervarix, GSK's HPV 16/18 cervical cancer candidate vaccine, is highly immunogenic and well-tolerated in women over 25 years of age

04 June 2006
Encouraging results of a clinical study with GSK's novel cancer immunotherapy report activity in patients with most common form of lung cancer

03 June 2006
GlaxoSmithKline reports positive new data on Tykerb (lapatinib ditosylate)

31 May 2006
Adolor's complete response to approvable letter for Entereg (alvimopan) in POI accepted for review by FDA

30 May 2006
GlaxoSmithKline takes further action to help the world's poorest countries fight HIV/AIDS

24 May 2006
GlaxoSmithKline demonstrates progress of oncology portfolio

24 May 2006
GlaxoSmithKline reports on data transparency

22 May 2006
Study identifies predictors of bipolar disorder risk

18 May 2006
Jennie Younger, SVP Corporate Communications & Community Partnerships to leave GSK

17 May 2006
GlaxoSmithKline extends JP Garnier's contract

17 May 2006
New data show Coreg CR reduced blood pressure in patients with essential hypertension

16 May 2006
GlaxoSmithKline and Vertex announce preliminary 48-week results from head-to-head clinical study

11 May 2006
GlaxoSmithKline announces transitional plan for former patient assistance program enrollees

10 May 2006
GSK obtains injunction to protect shareholders against animal extremists

10 May 2006
GSK wins World Business Award for efforts to end lymphatic filariasis

08 May 2006
GlaxoSmithKline condemns animal extremist letter campaign to shareholders

05 May 2006
In a new study Rotarix offers 96 per cent protection against severe rotavirus gastroenteritis and prevents 100 per cent of rotavirus-associated hospitalisations

04 May 2006
GlaxoSmithKline and Adolor present positive results from a clinical study of alvimopan (Entereg)

04 May 2006
GlaxoSmithKline awarded $274 million HHS contract

03 May 2006
GSK receives positive opinion from CHMP on Seretide dosing for initial maintenance therapy

02 May 2006
GlaxoSmithKline to continue patient assistance benefits to the elderly and disabled not enrolled in Medicare Part D

27 April 2006
Results announcement for the first quarter 2006

24 April 2006
Baby boom icon Sally Field takes on new leading role as women's health advocate

19 April 2006
Ten top health charities awarded £210,000 in GlaxoSmithKline IMPACT Awards 2006

13 April 2006
GlaxoSmithKline and Adolor announce the completion of enrolment of pivotal clinical studies of Entereg (alvimopan)

07 April 2006
GlaxoSmithKline's Adartrel becomes the first RLS treatment to receive a positive decision from the European Commission

06 April 2006
New data presented on satisfaction, productivity and long-term safety of a single tablet containing sumatriptan formulated with RT Technology and naproxen sodium

06 April 2006
Cervarix, GSK's candidate vaccine for cervical cancer, demonstrated sustained efficacy for up to 4.5 years and broader protection against cancer-causing HPV types

06 April 2006
Arixtra significantly reduced major bleeding compared to Lovenox in a study of patients with acute coronary syndromes

05 April 2006
New pivotal trial data demonstrated superior clinical benefits of single tablet containing sumatriptan formulated with RT Technology and naproxen sodium

03 April 2006
GlaxoSmithKline receives positive data and halts enrolment in Phase III trial of Tykerb (lapatinib) in advanced breast cancer

03 April 2006
GlaxoSmithKline and Sirna Therapeutics announce major alliance in RNAi-based therapeutics for respiratory disease

31 March 2006
New Bonviva quarterly injection approved in Europe for postmenopausal osteoporosis

30 March 2006
GlaxoSmithKline initiates human trial programme with two H5N1 pandemic flu vaccines

30 March 2006
GlaxoSmithKline and Pharmacopeia enter into drug discovery and development alliance

28 March 2006
GSK announces positive results of Seretide study in patients with chronic obstructive pulmonary disease (COPD)

24 March 2006
New data in Lancet confirm potential to eliminate lymphatic filariasis

23 March 2006
GlaxoSmithKline submits Biologics License Application for FDA approval of Flulaval

23 March 2006
FDA approves Flovent HFA( fluticasone propionate hfa) Inhalation Aerosol for children four to eleven

22 March 2006
Study shows Levitra treats erectile dysfunction effectively in men taking medications to lower high blood pressure

22 March 2006
GlaxoSmithKline begins testing new technology

22 March 2006
Eight local community health organizations honored for excellence at 9th Annual GlaxoSmithKline IMPACT Awards

21 March 2006
GlaxoSmithKline's CEO appointed to Chancellor Gordon Brown's International Business Advisory Council

21 March 2006
Patrick Vallance to head Drug Discovery at GlaxoSmithKline

17 March 2006
New study shows women with osteoporosis preferred once-monthly dosing of Boniva over a once-weekly medicine

14 March 2006
New Drug Application for Coreg CR accepted for review by U.S. Food and Drug Administration

14 March 2006
Arixtra reduced risk of death or recurrent heart attack in patients with acute coronary syndromes (ST Elevation Myocardial Infarction)

13 March 2006
GlaxoSmithKline joins combined White House, industry, UN agencies effort to fight paediatric AIDS in developing countries

13 March 2006
New analysis reveals use of Coreg (CARVEDILOL) at hospital discharge associated with improved survival in patients with heart failure

09 March 2006
Marketing application for Cervarix, GSK's candidate caccine for cervical cancer, submitted in the European Union

09 March 2006
New analysis shows high narcotic use among headache sufferers

08 March 2006
New observational study suggests use of combination vaccines may improve immunization coverage rates in infants

07 March 2006
GSK statement regarding Flonase generic

06 March 2006
GlaxoSmithKline and Myogen announce pulmonary arterial hypertension partnership

03 March 2006
Response to global disasters increases GSK's giving by 16 per cent to £380m in 2005

03 March 2006
GSK announces new product labels for Serevent and Advair

01 March 2006
New study shows Ohioans needlessly suffer because they are not properly caring for chronic conditions

27 February 2006
Rotarix: first vaccine against rotavirus available in Europe

23 February 2006
New appointments at GlaxoSmithKline emphasize focus on development and medical governance

22 February 2006
GlaxoSmithKline supports the establishment of Improving Health for Ohioans month

17 February 2006
GlaxoSmithKline application accepted by the FDA to expand use of Hycamtin in combination with cisplatin for the treatment of advanced cervical cancer

14 February 2006
GlaxoSmithKline acquires PLIVA's Research Institute

14 February 2006
GlaxoSmithKline announces commencement of eltrombopag phase III worldwide clinical trial in adults with previously-treated idiopathic thrombocytopenic purpura

14 February 2006
GlaxoSmithKline's topical antibacterial retapamulin accepted for review by the US Food and Drug Administration

13 February 2006
ARIXTRA was effective and well tolerated in acutely ill medical patients - treatment reduced risk of venous thromboembolism (VTE)

08 February 2006
Full-year results announcement 2005

07 February 2006
Adolor and GlaxoSmithKline report positive top-line results in phase 3 study 314 of Entereg (alvimopan) in postoperative ileus

06 February 2006

06 February 2006
Dr. Moncef Slaoui to Head GlaxoSmithKline Research and Development

03 February 2006
Arixtra administered the morning after orthopedic surgery prevented venous thromboembolism with low risk of bleeding

02 February 2006
FDA approves new formulation of Imitrex (sumatriptan succinate) injection

01 February 2006
GSK confirms: Panadol is safe for consumers, when used as directed

01 February 2006
IV Hycamtin receives European marketing approval as treatment for relapsed small cell lung cancer

01 February 2006
GlaxoSmithKline announces the approval and availability of AVANDARYL (rosiglitazone maleate and glimepiride): a new fixed-dose combination tablet to treat type 2 diabetes

27 January 2006
European positive opinion for first quarterly I.V. injection for postmenopausal osteoporosis

23 January 2006
FDA Joint Advisory Committee recommends approval of orlistat 60mg capsules for over-the-counter use

19 January 2006
New study supports importance of considering gastric stasis

17 January 2006
GlaxoSmithKline plc Directorate change

06 January 2006
FDA approves first IV treatment for postmenopausal osteoporosis - Boniva Injection

05 January 2006
Rotarix proven to have up to 100% efficacy against severe rotavirus episodes - data published in the NEJM establishes safety profile of new rotavirus vaccine

04 January 2006
Requip (ropinirole HCl) tablets significantly improve symptoms of Restless Legs Syndrome (RLS) in patients with RLS